11 reports

Trogarzo

8770 10000 7800

Trogarzo CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## Trogarzo : HIV LIST OF FIGURES ## Figure ##: Datamonitor Healthcare’s drug assessment summary of Trogarzo for HIV ## Figure ##: Datamonitor Healthcare’s drug assessment summary of Trogarzo for HIV ## Figure ##: Trogarzo s

  • Biopharmaceutical
  • HIV AIDS
  • Medical Biotechnology
  • Monoclonal Antibody
  • United States

Gazyva

8770 10000 7800

The drug is Roche’s third-generation anti-CD## monoclonal antibody (MAb), and is positioned as a potential replacement for Rituxan in the FL market.

  • Medical Biotechnology
  • Monoclonal Antibody
  • European Union
  • Japan
  • United States

MOR208

8770 10000 7800

Analyst Outlook MorphoSys is positioning its cluster of differentiation (CD)##-targeted monoclonal antibody (MAb) MOR## in relapsed/ refractory diffuse large B-cell lymphoma (DLBCL) patients who are ineligible for high-dose chemotherapy (HDT) and autologous stem cell transplan

  • Lymphoma
  • Medical Biotechnology
  • Monoclonal Antibody
  • European Union
  • United States

Isatuximab

8770 10000 7800

Initial approvals in the relapsed/ refractory settings would make isatuximab the second CD##-directed monoclonal antibody therapy to enter the market, and would place it in direct competition with more established therapies such as Darzalex (daratumumab; Johnson and Johnson), F

  • Medical Biotechnology
  • Monoclonal Antibody
  • European Union
  • Japan
  • United States

Arzerra

8770 10000 7800

Arzerra’s modest market share will likely begin to erode as newer monoclonal antibodies and small molecule inhibitors gain uptake in both treatment-naïve and relapsed/ refractory CLL.

  • Monoclonal Antibody
  • Europe
  • European Union
  • Japan
  • United States

MEDI8897

8770 10000 7800

Analyst Outlook MEDI## is a next-generation monoclonal antibody (MAb) with an extended half-life compared to Synagis (palivizumab; AstraZeneca/ AbbVie) and the potential for an improved administration schedule.

  • Biopharmaceutical
  • Monoclonal Antibody
  • European Union
  • United States
  • Forecast

Evinacumab

8770 10000 7800

Evinacumab CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## evinacumab : Dyslipidemia LIST OF FIGURES ## Figure ##: Evinacumab for dyslipidemia – SWOT analysis ## Figure ##: Datamonitor Healthcare’s drug assessment summary of evinacumab for dyslipidemia ## Figure ##: Datamonitor H

  • Cholesterol
  • Medical Biotechnology
  • Monoclonal Antibody
  • Therapy
  • United States

Portrazza

8770 10000 7800

The drug also has the potential to produce antibody-dependent cell-mediated cytotoxicity in cancer cells that express EGFR.

  • Monoclonal Antibody
  • Therapy
  • European Union
  • Japan
  • United States

polatuzumab vedotin

8770 10000 7800

polatuzumab vedotin CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## polatuzumab vedotin : NHL: Diffuse large B-cell lymphoma (DLBCL) LIST OF FIGURES ## Figure ##: Polatuzumab vedotin for diffuse large B-cell lymphoma – SWOT analysis ## Figure ##: Datamonitor Healthcare’s drug as

  • Monoclonal Antibody
  • Therapy
  • European Union
  • Japan
  • United States

Inclisiran

8770 10000 7800

The product is expected to have comparable efficacy to monoclonal antibody (MAb) PCSK## inhibitors, Repatha (evolocumab; Amgen) and Praluent (alirocumab; Sanofi/ Regeneron).

  • Lipid Modifying Drug
  • Monoclonal Antibody
  • European Union
  • United States
  • Forecast

Zevalin

8770 10000 7800

Zevalin TABLE OF CONTENTS ## PRODUCT PROFILES ## Zevalin : NHL: Follicular lymphoma LIST OF FIGURES ## Figure ##: Zevalin for follicular lymphoma – SWOT analysis ## Figure ##: Datamonitor Healthcare’s drug assessment summary of Zevalin in follicular lymphoma ## Figure ##: Datamonitor Healthca

  • Monoclonal Antibody
  • Europe
  • Japan
  • United States
  • Litigation And Patent